Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer study maps genetic resistance to guide next steps

NCT ID NCT05219162

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 34 times

Summary

This study looked at gene changes in 182 people with advanced lung cancer whose disease got worse after first treatment with osimertinib. Researchers collected tissue and blood samples to find out why the drug stopped working. The goal is to help doctors choose better treatments after osimertinib fails.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Beijing, 100210, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Chengdu, 610014, China

  • Research Site

    Dalian, 116023, China

  • Research Site

    Foshan, 528000, China

  • Research Site

    Fuzhou, 350014, China

  • Research Site

    Harbin, 150081, China

  • Research Site

    Hefei, 230001, China

  • Research Site

    Hefei, 230601, China

  • Research Site

    Linhai, 317000, China

  • Research Site

    Luoyang, 471003, China

  • Research Site

    Rizhao, 276826, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Taizhou, 225300, China

  • Research Site

    Tianjin, 300060, China

  • Research Site

    Zhengzhou, 450000, China

Conditions

Explore the condition pages connected to this study.